NTRA Natera, Inc.
Services-Medical Laboratories · Nasdaq · SEC CIK 1604821 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY37.4%
TTM net income YoY46.7%
TTM EPS YoY51.1%
Revenue 3-yr CAGR43.3%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-9.0%
Net margin-5.7%
FCF margin1.8%
EBITDA margin-7.1%
Returns
ROE-10.6%
ROA-7.2%
ROIC (approx.)-41.9%
Asset turnover1.27x
Leverage & solvency
Liabilities / assets32.0%
Debt / equity0.00x
Current ratio2.81x
Interest coverage-70.84x
Cash quality & payout
Operating cash flow / net income-1.29x
Accruals ratio-16.5%
Payout ratio—
Capex / revenue5.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $2.31B | $1.70B |
| R&D expense | $624.11M | $404.14M |
| SG&A expense | $1.18B | $841.31M |
| Operating income | -$309.91M | -$222.29M |
| Interest expense | $4.07M | $10.69M |
| Pretax income | -$268.09M | -$189.73M |
| Income tax | -$59.93M | $695,000 |
| Net income | -$208.16M | -$190.43M |
| EBITDA | -$268.15M | -$191.33M |
| EPS (basic) | -1.52 | -1.53 |
| EPS (diluted) | -1.52 | -1.53 |
| Weighted avg. shares (diluted) | 136.72M | 124.72M |
| Balance sheet | ||
| Cash & equivalents | $1.08B | $945.59M |
| Short-term investments | — | $22.69M |
| Receivables | $296.53M | $314.17M |
| Inventory | $68.44M | $44.74M |
| Current assets | $1.50B | $1.38B |
| PP&E, net | $241.18M | $162.05M |
| Goodwill | $141.07M | — |
| Intangibles | $373.71M | $10.93M |
| Total assets | $2.40B | $1.66B |
| Current liabilities | $441.23M | $344.05M |
| Short-term debt | $80.32M | $80.36M |
| Total liabilities | $685.93M | $465.31M |
| Shareholders' equity | $1.71B | $1.20B |
| Shares outstanding | 139.69M | 132.65M |
| Cash flow statement | ||
| Operating cash flow | $215.30M | $135.66M |
| Capital expenditure | $106.19M | $66.42M |
| Free cash flow | $109.11M | $69.24M |
| Investing cash flow | -$132.21M | $137.62M |
| Financing cash flow | $47.46M | $30.20M |
| Depreciation & amortization | $41.76M | $30.97M |
| Stock-based compensation | $354.40M | $274.43M |
Free plan shows the latest 2 periods; Pro shows all 13 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.